🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

10x Genomics, Inc. TXG R2K

Healthcare · Health Information Services · United States
https://www.10xgenomics.com

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

READ MORE ›
$28.30
+197.01% 1Y

Market & Price

Market Cap
$3.59B
Current Price
$28.30
High / Low (52W)
$28.30 / $9.11
Beta
2.05

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
141.53
PEG Ratio
-
Book Value
$6.24
Price to Book
4.54
P/S
5.63
EV/EBITDA
-102.22
Dividend Yield
-

Profitability & Returns

ROCE
-4.49%
ROE
-2.98%
ROA
-4.48%
Profit Margin
-3.55%
Op Margin
-11.30%
EPS (Latest Qtr)
$-0.10
EPS (TTM)
$-0.17

Balance Sheet & Liquidity

Debt/Equity
0.10
Quick Ratio
5.25
Current Ratio
5.90
Debt
$81.39M
Total Assets
$1.04B
Current Assets
$684.45M
Working Capital
$531.00M

Ownership

Promoter Holding
1.63%
Chg in Prom Hold
-
FII / Inst Holding
110.44%
Chg in FII Hold
0.06%

Financial Snapshot

Enterprise Value
$3.14B
Total Revenue (TTM)
$638.78M
EBITDA
$-30.67M
Free Cash Flow
$124.55M
Operating Cash Flow
$127.82M
Shares Outstanding
116.88M
Gross Margin
69.68%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
7.57%
Profit 5Y
24.59%
Revenue (YoY)
-2.60%
Earnings (YoY)
-

PROS

  • Profit CAGR of 24.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TXG 10x Genomics, Inc. R2K 28.30 - $3.59B - -4.49% -2.98% 7.57% 24.59%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----55.82M61.21M-71.91M42.91M71.82M105.82M115.84M125.30M114.50M114.61M131.07M134.28M146.82M153.64M141.01M153.10M--154.88M172.91M149.00M166.03M150.84M
Cost of Revenue ------------------------49.44M47.82M48.70M52.98M44.66M
Gross Profit 23.44M27.19M31.37M35.65M39.61M40.81M45.73M58.71M56.80M32.85M57.41M88.76M110.93M100.78M89.02M86.91M100.69M98.39M99.61M95.53M92.91M104.22M--105.44M125.08M100.31M113.05M106.18M
Operating Expenses ------------------------153.97M135.66M132.55M132.59M123.22M
Operating Income ---14.93M--3.04M-10.36M-9.10M--19.88M-39.42M-65.25M-10.22M-10.33M-15.88M-41.73M-63.12M-40.00M-51.99M-63.36M-94.80M-61.50M-41.74M---48.53M-10.57M-32.24M-19.54M-17.05M
EBITDA -------------------------38.71M46.65M-19.99M63.54M-5.14M
Interest Expense ----------------------2.00K003.00K---
Pretax Income -------------------------33.51M37.00M-28.20M-15.19M-12.85M
Tax Provision ------------------------852.00K2.46M-733.00K1.06M623.00K
Net Income -15.69M-5.92M-15.35M-75.52M-3.64M-10.88M-9.60M-7.13M-21.14M-40.17M-65.85M-11.55M-11.05M-17.17M-42.41M-64.46M-41.91M-50.75M-62.41M-92.99M-59.95M-37.90M---34.36M34.54M-27.47M-16.25M-13.47M
Diluted EPS ---------0.22-0.41-0.65-0.11-0.10-0.15-0.38-0.57-0.37-0.44-0.53-0.79-0.50-0.32---0.280.28-0.22-0.13-0.10

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -146.31M245.89M298.85M-516.41M618.73M610.78M642.82M
Cost of Revenue -----120.39M209.41M196.30M198.94M
Gross Profit 60.52M117.65M184.86M240.38M-396.02M409.31M414.48M443.88M
Operating Expenses -----563.97M613.66M609.04M554.77M
Operating Income -18.38M-110.76M-30.57M-534.14M--167.94M-204.35M-194.56M-110.89M
EBITDA ------128.49M-205.11M-133.99M3.91M
Interest Expense -----476.00K33.00K4.00K0
Pretax Income ------161.97M-248.76M-177.70M-39.91M
Tax Provision -----4.03M6.34M4.93M3.64M
Net Income -18.76M-112.48M-31.25M-542.73M--166.00M-255.10M-182.63M-43.54M
Diluted EPS ---0.80-5.37--1.46-2.18-1.52-0.35

Compounded Sales Growth

5 Years:7.57%
1 Year:-2.60%

Compounded Profit Growth

5 Years:24.59%
1 Year:-

Stock Price Performance

1 Year:+197.01%
6 Months:+48.43%
3 Months:+22.80%
1 Month:+40.12%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Jan 2020Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --124.31M605.92M45.60M929.34M-1.03B965.14M918.64M1.04B
Current Assets -------635.03M596.02M584.39M684.45M
Cash & Equivalents -47.86M65.08M424.17M-663.60M-219.75M359.28M344.07M473.97M
Inventory -------81.63M73.71M83.11M56.34M
Receivables -------104.21M114.83M87.86M47.01M
Total Liabilities --101.05M185.84M78.14M190.27M-223.24M224.10M208.50M245.04M
Current Liabilities --32.36M63.05M-118.13M-130.96M127.16M117.63M153.45M
Long Term Debt --25.49M19.84M-0-----
Total Debt -------95.18M95.37M82.61M84.36M
Total Equity -96.43M-112.51M-219.99M420.08M-739.07M-805.74M741.04M710.13M796.33M
Shares Outstanding -------115.20M119.10M122.29M127.69M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -10.70M-76.41M34.63M-217.90M--33.61M-15.20M6.66M136.05M
Investing Cash Flow -3.76M-6.71M-42.77M-38.39M--350.89M133.49M-32.63M-13.44M
Financing Cash Flow 20.58M105.37M414.59M468.91M-15.82M13.67M10.91M6.80M
Capital Expenditure -3.76M-6.28M-42.74M-36.67M--131.66M-49.52M-13.39M-5.93M
Free Cash Flow -14.46M-82.69M-8.12M-254.56M--165.27M-64.72M-6.73M130.12M
Net Change in Cash ------368.68M131.96M-15.05M129.41M
Share Buybacks 80.00K--------

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -80.4%75.2%80.4%-76.7%66.2%67.9%69.1%
Operating Margin % --75.7%-12.4%-178.7%--32.5%-33.0%-31.9%-17.2%
Net Margin % --76.9%-12.7%-181.6%--32.1%-41.2%-29.9%-6.8%
ROE % 16.7%51.1%-7.4%-73.4%--20.6%-34.4%-25.7%-5.5%
ROCE % --120.5%-5.6%-65.8%--18.7%-24.4%-24.3%-12.5%

Shareholding Pattern

Insiders
1.63%
Institutions
110.44%
Public Float
112.27%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 15.18% 17.74M $502.16M
2 ARK Investment Management, LLC 10.03% 11.72M $331.66M
3 Blackrock Inc. 8.62% 10.08M $285.31M
4 Vanguard Portfolio Management LLC 5.91% 6.91M $195.67M
5 Quantinno Capital Management, LP 4.63% 5.41M $153.18M
6 Vanguard Capital Management LLC 4.51% 5.27M $149.16M
7 Sumitomo Mitsui Trust Group, Inc. 4.37% 5.11M $144.64M
8 Amova Asset Management Americas Inc 4.37% 5.10M $144.47M
9 Goldman Sachs Group Inc 3.40% 3.97M $112.42M
10 Geode Capital Management, LLC 2.48% 2.90M $82.20M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TXG

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks